Cardiac Amyloidosis: Tribulations and New Frontiers

Area of Science:

• Cardiology
• Internal Medicine
• Genetics

Background:

• Cardiac amyloidosis (CA) is a progressive disease caused by amyloid fibril deposition in the heart.
• Two main types exist: transthyretin cardiac amyloidosis (ATTR-CA) and light chain cardiac amyloidosis (AL-CA).
• ATTR-CA is further classified into wild-type (ATTRwt) and hereditary (ATTRv) forms, predominantly affecting older males, particularly African Americans.

Purpose of the Study:

• To review the pathophysiology, diagnosis, and current management of cardiac amyloidosis.
• To identify knowledge gaps and potential research directions in CA.
• To highlight the complexity of CA diagnosis and treatment, emphasizing multidisciplinary approaches.

Main Methods:

• Literature review of pathophysiology, diagnostic modalities, and therapeutic strategies for CA.
• Analysis of current clinical trial landscape and emerging disease-modifying agents.
• Synthesis of expert recommendations and identification of unmet needs in CA care.

Main Results:

• Increased awareness and diagnostic capabilities have led to more CA diagnoses.
• Novel disease-modifying agents are emerging, but high costs and limited evidence pose challenges.
• Optimal diagnostic and treatment strategies, including combination therapies, require further investigation.

Conclusions:

• Effective CA management requires a multidisciplinary approach and personalized patient care.
• Further clinical trials, standardized protocols, and patient resources are crucial for improving outcomes.
• Addressing the high cost and evidence gaps of new therapies is essential for broader patient benefit.